For US residents only.

Sign Up for Support

Sandostatin® LAR Depot (octreotide acetate for injectable suspension)

Important Safety Information And Approved Use

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring by your doctor.

Before taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common side effects: Most patients experience side effects at some time. Some common side effects that you may experience include: back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

Please see full Prescribing Information

Approved Use:

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated. In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.

Important Safety Information:

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring b

... See More
Approved Use:

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and long-term treatment of the profuse watery diarrhea

... See More

Sign Up for RealSupport™

RealSupport™ is an information and support program specifically designed to help patients diagnosed with severe diarrhea and flushing associated with carcinoid syndrome to access the materials and tools they need to help manage their symptoms. Simply complete the questionnaire below to enroll with the RealSupport™ program.

Through RealSupport™, you’ll receive:

Privacy Notice

Novartis Pharmaceuticals Corporation and Novartis Group of Companies understands your personal and health information is private.

 

The personal information we collect from you will be used to bring you information about products, programs, support, and services, to conduct market research, and as provided in our Privacy Policy.

 

You may unsubscribe from our programs and services at any time by calling 1-888-669-6682. For more information about our privacy practices, please visit our Privacy Policy at www.usprivacy.novartis.com.

  1. 1/2:Enter Your Information
  2. 2/2:Review and Submit

* Required Field

Have you or someone you know experienced severe diarrhea or flushing associated with metastatic carcinoid tumors (carcinoid syndrome)? *

What is your relationship to the person diagnosed with carcinoid syndrome? *

Are you currently taking Sandostatin® (octreotide acetate) Immediate-release Injection or Sandostatin® LAR Depot (octreotide acetate for injectable suspension)? *

Please make sure all required fields are complete

Important Safety Information:

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring by your doctor.

Before taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common side effects: Most patients experience side effects at some time. Some common side effects that you may experience include: back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

Please see full Prescribing Information

Approved Use:

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated. In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.